IXICO announces that Susan Lowther FCMA has been appointed to the board as Chief Financial Officer with effect from 1 October 2014.
Susan was previously Group Chief Financial Officer and a director of Novacyt SA, a European company listed on the French Alternext exchange. Novacyt specialises in cancer and infectious disease diagnostic products and services, operating from four sites in France and the UK. Prior to that she was Chief Financial Officer and a director of Lab21 Group Limited which was acquired by Novacyt in June 2014 by way of a share for share transaction valuing the enlarged group at circa €40 million. Susan was previously Chief Financial Officer at BioWisdom Limited and has held finance roles in life science companies including RiboTargets, Lonza Biologics, Celltech Group and Monsanto.